277 related articles for article (PubMed ID: 16568952)
1. CpG island methylation and histone modifications: biology and clinical significance.
Esteller M
Ernst Schering Res Found Workshop; 2006; (57):115-26. PubMed ID: 16568952
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors: understanding a new wave of anticancer agents.
Villar-Garea A; Esteller M
Int J Cancer; 2004 Nov; 112(2):171-8. PubMed ID: 15352027
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
Santini V; Gozzini A; Ferrari G
Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis.
Shankar S; Srivastava RK
Adv Exp Med Biol; 2008; 615():261-98. PubMed ID: 18437899
[TBL] [Abstract][Full Text] [Related]
7. Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond.
Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
Expert Opin Investig Drugs; 2007 May; 16(5):569-71. PubMed ID: 17461732
[TBL] [Abstract][Full Text] [Related]
8. Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics.
Hadnagy A; Beaulieu R; Balicki D
Mol Cancer Ther; 2008 Apr; 7(4):740-8. PubMed ID: 18413789
[TBL] [Abstract][Full Text] [Related]
9. The potential role of epigenetic therapy in multiple myeloma.
Smith EM; Boyd K; Davies FE
Br J Haematol; 2010 Mar; 148(5):702-13. PubMed ID: 19912222
[TBL] [Abstract][Full Text] [Related]
10. Reactivation of silenced genes and transcriptional therapy.
Chiurazzi P; Neri G
Cytogenet Genome Res; 2003; 100(1-4):56-64. PubMed ID: 14526164
[TBL] [Abstract][Full Text] [Related]
11. Treatment of tumor cells with histone deacetylase inhibitors results in altered recruitment of methyl-CpG binding proteins to a methylated CpG island.
Koizume S; Tachibana K; Shiraishi M
Biol Chem; 2003 May; 384(5):787-90. PubMed ID: 12817475
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
Schneider-Stock R; Ocker M
IDrugs; 2007 Aug; 10(8):557-61. PubMed ID: 17665331
[TBL] [Abstract][Full Text] [Related]
13. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
14. Histones and lung cancer: Are the histone deacetylases a promising therapeutic target?
Petta V; Gkiozos I; Strimpakos A; Syrigos K
Cancer Chemother Pharmacol; 2013 Nov; 72(5):935-52. PubMed ID: 24036844
[TBL] [Abstract][Full Text] [Related]
15. [Targeted epigenetic therapy of cancer. Achievements and perspectives].
Valdespino-Gómez VM; Valdespino-Castillo VE
Cir Cir; 2012; 80(5):470-80. PubMed ID: 23351455
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic regulation of gene expression as an anticancer drug target.
Ferguson LR; Tatham AL; Lin Z; Denny WA
Curr Cancer Drug Targets; 2011 Feb; 11(2):199-212. PubMed ID: 21158714
[TBL] [Abstract][Full Text] [Related]
17. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
Yoshida M; Shimazu T; Matsuyama A
Prog Cell Cycle Res; 2003; 5():269-78. PubMed ID: 14593721
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase-dependent establishment and maintenance of broad low-level histone acetylation within a tissue-specific chromatin domain.
Im H; Grass JA; Christensen HM; Perkins A; Bresnick EH
Biochemistry; 2002 Dec; 41(51):15152-60. PubMed ID: 12484752
[TBL] [Abstract][Full Text] [Related]
19. Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning.
Hinshelwood RA; Melki JR; Huschtscha LI; Paul C; Song JZ; Stirzaker C; Reddel RR; Clark SJ
Hum Mol Genet; 2009 Aug; 18(16):3098-109. PubMed ID: 19477956
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
